Curcumin has been studied in 724 papers since 1998: 201 trials and 6 observational studies in people, 93 in animals, 34 in cells, 381 reviews; 113 in the past year. The newest story, Oct 28, 2026: “Food colorings linked to higher cardiovascular disease risk”.
Independent labs report longer worm lifespan and reduced human inflammation with curcumin, although other human results show no clear inflammatory effect. Human trials report both improved flow-mediated dilation and no clear effect. Registrations include one aging-related trial; across uses, 31 trials ended over a year ago without posted results; some papers declare company ties.
697 findings in 280 papers from 2001 to 2026, 20 of them since April 2026
Independent labs found the same change in cells, worms or flies, mice and people. 157 independent labs in 39 countries; 110 trials, 1 about aging, 31 with no results posted.
“curcumin-treated group showed a significant decrease in fasting blood glucose (115.49 vs.130.71; P < 0.05), HbA1c (6.12 vs. 6.47; P < 0.05)”
Cells, worms or flies, mice and humans: replicated by independent labs.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
About aging: the drug’s trials about aging. The total counts its trials for every use.
No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
157 independent labs in 39 countries
89 findings against
110 trials, 1 about aging, 31 with no results posted
DrugAge records 35 results from 10 papers: 31 in D. melanogaster and 4 in C. elegans. Average lifespan is the mean or the median, as each paper reports it.
Studies of curcumin measured 332 outcomes; the most studied are inflammation (25 studies), oxidative stress and ROS signaling (23) and lifespan (20).
Inflammation
↓downin humans11↓downin reviews8↓downin mice2↓downin human cells1+3
25 studies
Curcumin decreases inflammation in humans with diabetes and atherosclerotic cardiovascular risk.
“TNF-α levels significantly declined overtime (P < 0.001) only in the curcumin group and were significantly lower (P = 0.044) versus controls at the end of the study.”
Human trialwith diabetes and atherosclerotic cardiovascular risk14 weeksn = 72
Curcumin showed no clear effect on inflammation in humans.
“The results showed no significant changes in C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor α (TNF-α), interleukin-1 β (IL-1β), or blood morphology due to curcumin supplementation.”
“high-sensitivity C-reactive protein (hs- CRP), Interleukin 1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α) in comparison to the placebo (p<0.05)”
Human trialnanomicelle and conventional formulations8 weeksn = 90
“Experimental evidence suggests that curcumin can reduce inflammation and oxidative stress, regulate adipokines, improve lipid metabolism, and support vascular health.”
Curcumin decreases oxidative stress and ROS signaling in humans.
“Curcumin and nano-curcumin supplementation also exhibited significant changes in plasma levels of total antioxidant capacity (TAC), malondialdehyde (MDA)”
Human trialnanomicelle and conventional formulations8 weeksn = 90
Curcumin decreases oxidative stress and ROS signaling (metabolic syndrome).
“Experimental evidence suggests that curcumin can reduce inflammation and oxidative stress, regulate adipokines, improve lipid metabolism, and support vascular health.”
Current research in pharmacology and drug discovery·
Curcumin decreases oxidative stress and ROS signaling in ageing and diabetic populations.
“Furthermore, we examine emerging micronutrients and their potential therapeutic benefits, such as Magnesium, Folic Acid, and Curcumin, in reducing oxidative stress and modulating immune function.”
Curcumin inhibits cellular senescence in diabetic retinopathy.
“Curcumin can alleviate the progression of DR by promoting RPE survival, TJ integrity, retinoid isomerase activity, RPE senescence inhibition, and neovascularization.”
Curcumin decreases cellular senescence in mice (aged mice).
“CUR supplementation led to the downregulation of senescence-associated hepatic gene expressions in both usually fed and nutritionally challenged aged mice.”
Curcumin showed no clear effect on body weight in humans (MetS).
“There was no significant difference between treatment and control groups in terms of weight, body mass index, waist circumference and serum cathepsin D levels before and after the intervention.”
Human trialMetSphosphatidylcholine complex2 capsules containing 500 mg6 weeksn = 80
International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition·
Curcumin showed no clear effect on body weight in humans (patients with metabolic syndrome).
“did not improve weight and glucose homeostasis in the patients with metabolic syndrome”
Human trialpatients with metabolic syndromecapsule1890 mg/day12 weeksn = 33
Curcumin decreases body weight in mice (HFHSD-fed) (10.84 ± 1.09 g vs. 15.28 ± 1.26 g).
“cumulative body weight gain after 8 weeks in the aged female mice supplemented with curcumin and fed an HFHSD was significantly lower (10.84 ± 1.09 g) compared to those fed a HFHSD alone (15.28 ± 1.26 g)”
Curcumin decreases triglyceride in humans (versus placebo at end of study) (p < .05 versus placebo).
“Curcumin supplementation significantly decreased homeostatic model assessment for insulin resistance (HOMA-IR), erythrocyte sedimentation rate, serum levels of high-sensitivity C-reactive protein and triglycerides”
Human trialversus placebo at end of study500 mg once a day8 weeksfemalesn = 48
Curcumin decreases C-reactive protein in obese patients with type 2 diabetes, versus placebo.
“High-sensitivity C-reactive protein, interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha were also significantly lower in the curcumin group, with p values less than 0.001.”
Human trialin obese patients with type 2 diabetes, versus placebo12 months
Curcumin decreases C-reactive protein in humans (versus placebo at end of study) (p < .05 versus placebo).
“Curcumin supplementation significantly decreased homeostatic model assessment for insulin resistance (HOMA-IR), erythrocyte sedimentation rate, serum levels of high-sensitivity C-reactive protein and triglycerides”
Human trialversus placebo at end of study500 mg once a day8 weeksfemalesn = 48
Curcumin decreases fasting blood glucose in humans.
“The means of diabetes-related blood chemistries used to assess diabetic progression, such as HbA1c, FPG, were significantly lower in the curcumin-treated group compared to the placebo group at visits at 3,6, 9, and 12 months.”
Curcumin decreases fasting blood glucose in humans (polycystic ovary syndrome) (MD = -3.67, 95% CI [-5.25, -2.08], p < .00001).
“CUR was associated with a statistically significant improvement in the glycemic control including fasting blood glucose (MD = -3.67; 95% CI = [-5.25, -2.08], p < .00001)”
Curcumin decreases total cholesterol in patients with diabetes on hemodialysis (β = -17.83 mg/dL, 95% CI: -29.22 to -6.45).
“Nanocurcumin treatment was associated with a significant reduction in triglycerides (β = -16.13 mg/dL, 95% CI: -31.51 to -0.75; P < .05), VLDL-cholesterol (β = -3.22 mg/dL, 95% CI: -6.30 to -0.15; P < .05), total cholesterol (β = -17.83 mg/dL, 95% CI: -29.22 to -6.45; P < .05)”
Human trialin patients with diabetes on hemodialysis80 mg/d12 weeksn = 60
“curcumin supplementation (MD = −.49, CI [−.70; −.28]), dual GLP-1 + GIP RAs (MD = −.46, CI [−.63; −.29]), single GLP-1 RAs (MD = −.41, CI [−.50; −.31]), physical activity (MD = −.35, CI [−.47; −.24]) and metformin + DPP-4 (MD = −.30, CI [−.55; −.05]) were the most effective and the only ones to obtain a clinically significant reduction of HbA1c (≥.3%23”
Curcumin decreases HbA1c in humans (diabetic macular edema; adjunct to intravitreal bevacizumab versus matched placebo) (Greater reduction: MD 0.63%, 95% CI 0.3–1.0; P < 0.001).
“Adjunctive treatment with oral curcumin in patients receiving IVB for DME was associated with a significantly greater reduction in HbA1c levels.”
Human trialdiabetic macular edema; adjunct to intravitreal bevacizumab versus matched placebooral capsules40 mg every 12 h3 monthsn = 52
“Although no significant group × time interaction was observed (p = 0.217), the curcumin-supplemented group showed a significant reduction in HbA1c levels (p = 0.044, 95% CI: 0.006 to 0.494), while levels remained stable in the placebo group (p > 0.999, 95% CI: −0.260 to 0.348).”
Curcumin showed no clear effect on HbA1c in humans.
“The primary endpoint, HbA1c, did not differ significantly between the two groups.”
Human trialpatients with impaired glucose tolerance or non-insulin-dependent diabetes mellitus, versus placebohighly absorbable preparation (Theracurmin)180 mg daily6 months
Curcumin decreases HbA1c in humans (uncomplicated type 2 diabetes) (p = 0.008).
“glycosylated hemoglobin, homeostasis model assessment (HOMA), and low-density lipoprotein (LDL) showed a statistically significant reduction in subjects that were treated with curcumin”
Curcumin decreases HOMA-IR in humans (uncomplicated type 2 diabetes) (p < 0.001).
“glycosylated hemoglobin, homeostasis model assessment (HOMA), and low-density lipoprotein (LDL) showed a statistically significant reduction in subjects that were treated with curcumin”
Curcumin showed no clear effect on LDL cholesterol in humans (polycystic ovary syndrome) (MD -6.02, 95% CI -26.66 to 14.62).
“there is no statistically significant difference in the improvement in low-density lipoprotein (MD: -6.02, 95% CI: -26.66 to 14.62) and triglyceride (MD: 8.22, 95% CI: -26.10 to 42.53) between curcumin and placebo.”
Curcumin decreases LDL cholesterol in humans (uncomplicated type 2 diabetes) (p = 0.021).
“glycosylated hemoglobin, homeostasis model assessment (HOMA), and low-density lipoprotein (LDL) showed a statistically significant reduction in subjects that were treated with curcumin”
Curcumin showed no clear effect on LDL cholesterol in humans (patients with metabolic syndrome and related disorders) (SMD -0.52; 95% CI, -1.14, 0.11; P=0.10).
“We found no significant effect of curcumin supplementation on LDL- (SMD -0.52; 95% CI, -1.14, 0.11; P=0.10) and HDL-cholesterol levels”
Reviewpatients with metabolic syndrome and related disordersn = 1,890
Curcumin showed no clear effect on flow-mediated dilation in humans (stage 3b or 4 CKD) (median change from baseline was -0.7 (-2.1, 1.1) and -0.1 (-1.5, 1.5) for curcumin and placebo, respectively, with p = 0.69).
“Compared with placebo, 12 months of curcumin did not improve FMD”
Human trialstage 3b or 4 CKDLongvida®2000 mg/day12 monthsn = 88
“There was a significant reduction of circulating IL-6 concentrations following curcuminoids supplementation (WMD: -0.60pg/mL, 95% CI: -1.06, -0.14, p=0.011).”
Studies link curcumin with 14 measures, among them microbiome composition, atrial fibrillation and metabolic syndrome.
Microbiome composition
↕mixedin humans2
2 studies
Curcumin is associated with microbiome composition in humans (prediabetes or overweight/obesity).
“Gut microbiome analysis revealed no significant changes in alpha diversity or beta diversity of microbiome; however, there was marginal enrichment of beneficial bacteria”
Human trialprediabetes or overweight/obesitycapsules80 mg12 weeksn = 23
Curcumin is associated with microbiome composition in humans (chronic kidney disease).
“Regarding GM, after 6 months of curcumin supplementation, Escherichia-Shigella was significantly lower, while Lachnoclostridium was significant higher.”
Curcumin lowers the risk of atrial fibrillation in mice (aging).
“p300 inhibitor curcumin and p300 knockdown treated aging mouse and senescence human atrial fibroblasts reduced the senescence ratio of atrial fibroblasts, ameliorated the atrial fibrosis, and decreased the AF inducibility”
Curcumin lowers the risk of metabolic syndrome in humans.
“The frequency of patients with fatty liver and metabolic syndrome at the end of the intervention was significantly lower in the curcumin group than in the control group.”
Curcumin lowers the risk of metabolic syndrome in humans with lifestyle modification (p = 0.012).
“After the intervention, there was a lower number of patients with severe fatty liver (FLI ≥ 60) and metabolic syndrome in the curcumin group compared to the placebo (p = 0.021 and p = 0.012, respectively).”
Curcumin lowers the risk of breast and prostate cancer.
“bioactive compounds, especially curcumin in turmeric and isoflavones in soybean, contribute to decreased risk of certain cancers, such as breast and prostate cancer”
Curcumin is associated with dasatinib in silico (based on similarity in gene expression effects).
“The natural senolytic piperlongumine (a compound found in long pepper), and the natural senomorphics parthenolide, phloretin and curcumin (found in various edible plants) were identified as potential substitutes of dasatinib.”
In silicobased on similarity in gene expression effects
Curcumin is associated with inflammatory biomarkers in humans (Compared with placebo in older adults with low-grade systemic inflammation) (Galectin-3 d=-0.31 (larger decrease); interleukin-6 d=0.38 (smaller increase)).
“Effect sizes for galectin-3 (d=-0.31) (larger decrease) and interleukin-6 (d=0.38) (smaller increase) were small in the Curcumin C3 Complex® group compared to placebo.”
Human trialCompared with placebo in older adults with low-grade systemic inflammationCurcumin C3 Complex®1000mg/day12 weeks8 females and 9 malessn = 17
Independent labs report that curcumin extends lifespan in T. castaneum, shortens it in worms at 10 µM, and reduces human inflammation. Other studies report worm lifespan extension, unchanged mouse lifespan or unchanged human inflammation. One registered trial concerns aging; 32 trials across uses ended over a year ago without posted results or citing papers, and some papers declare company ties.
Curcumin extends lifespan in worms and T. castaneum, independently replicated in the latter, while mouse lifespan results differ. Independent labs report reduced human inflammation, alongside null results. None of its registered trials is classified as aging-focused; 37 ended over a year ago without posted results or linked papers, and some papers have company authors or disclose company ties.
Summary rewritten as its findings changed.
As it read before
A human trial shows curcumin lowers HbA1c in prediabetes, and a worm study reports more moving worms. One mouse study finds reduced weight gain, hypertension and hypothalamic pNMDAR in ovariectomized, high-fat-fed females, but unchanged pNMDAR in lean or obese males.
The highest versus lowest intake group had hazard ratios of 1.36 for high blood pressure and 1.18 for cardiovascular disease.The highest versus lowest intake group had hazard ratios of 1.36 for high blood pressure and 1.18 for cardiovascular disease.